KR102676274B1 - 세레브로리신의 용도 - Google Patents

세레브로리신의 용도 Download PDF

Info

Publication number
KR102676274B1
KR102676274B1 KR1020207007069A KR20207007069A KR102676274B1 KR 102676274 B1 KR102676274 B1 KR 102676274B1 KR 1020207007069 A KR1020207007069 A KR 1020207007069A KR 20207007069 A KR20207007069 A KR 20207007069A KR 102676274 B1 KR102676274 B1 KR 102676274B1
Authority
KR
South Korea
Prior art keywords
cerebrolysin
composition
cardasil
treated
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207007069A
Other languages
English (en)
Korean (ko)
Other versions
KR20200045503A (ko
Inventor
스테판 윈터
허버트 뫼슬러
Original Assignee
에버 뉴로 파르마 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에버 뉴로 파르마 게엠베하 filed Critical 에버 뉴로 파르마 게엠베하
Publication of KR20200045503A publication Critical patent/KR20200045503A/ko
Application granted granted Critical
Publication of KR102676274B1 publication Critical patent/KR102676274B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
KR1020207007069A 2017-08-28 2018-08-28 세레브로리신의 용도 Active KR102676274B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17188180.8 2017-08-28
EP17188180.8A EP3449931B1 (en) 2017-08-28 2017-08-28 Use of cerebrolysin
PCT/EP2018/073106 WO2019042983A1 (en) 2017-08-28 2018-08-28 USE OF CERBROLYSINE

Publications (2)

Publication Number Publication Date
KR20200045503A KR20200045503A (ko) 2020-05-04
KR102676274B1 true KR102676274B1 (ko) 2024-06-18

Family

ID=59745228

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207007069A Active KR102676274B1 (ko) 2017-08-28 2018-08-28 세레브로리신의 용도

Country Status (15)

Country Link
US (1) US12589118B2 (https=)
EP (2) EP3449931B1 (https=)
JP (1) JP7281450B2 (https=)
KR (1) KR102676274B1 (https=)
CN (1) CN111050780B (https=)
AU (1) AU2018326339A1 (https=)
CA (1) CA3073991A1 (https=)
EA (1) EA202090108A1 (https=)
ES (2) ES2767070T3 (https=)
HR (1) HRP20200031T1 (https=)
MX (1) MX2020002267A (https=)
PH (1) PH12020500376A1 (https=)
PL (2) PL3449931T3 (https=)
UA (1) UA129400C2 (https=)
WO (1) WO2019042983A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220168325A1 (en) * 2019-03-25 2022-06-02 The University Of Vermont Methods to promote cerebral blood flow in the brain
WO2022013236A1 (en) 2020-07-13 2022-01-20 Ever Neuro Pharma Gmbh Method for producing a mammalian brain protein hydrolysate
IL307903A (en) * 2021-06-02 2023-12-01 Regeneron Pharma Treatment of cerebrovascular disease with Notts homolog protein factors 3 neurogenic locus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69126563T2 (de) 1990-04-12 1998-02-05 Ebewe Arzneimittel Verwendung einer Mischung von Peptiden and Aminosäuren für die Prophylaxis oder Behandlung von Dementia
EP1857463A1 (en) * 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
US9192578B2 (en) 2008-08-20 2015-11-24 Board Of Regents, The University Of Texas System Hot-melt extrusion of modified release multi-particulates

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BMC Medicine, 제15권, 논문번호 41 (2017. 2. 24.)
Neurol. Sci., 제34권, 제4호, 제553-556면 (2012. 8. 10.)
Ning Chen 등, "Cerebrolysin for vascular dementia", Cochrane Database Syst. Rev., 제1호, 논문번호 CD008900 (2013. 1. 31.)

Also Published As

Publication number Publication date
CN111050780B (zh) 2023-11-03
US20200376040A1 (en) 2020-12-03
WO2019042983A1 (en) 2019-03-07
UA129400C2 (uk) 2025-04-16
AU2018326339A1 (en) 2020-03-05
PL3449931T3 (pl) 2020-06-01
CN111050780A (zh) 2020-04-21
CA3073991A1 (en) 2019-03-07
JP2020531568A (ja) 2020-11-05
US12589118B2 (en) 2026-03-31
EA202090108A1 (ru) 2020-03-31
HRP20200031T1 (hr) 2020-03-20
JP7281450B2 (ja) 2023-05-25
EP3675879A1 (en) 2020-07-08
ES2901508T3 (es) 2022-03-22
ES2767070T3 (es) 2020-06-16
EP3449931B1 (en) 2019-10-16
MX2020002267A (es) 2020-10-22
KR20200045503A (ko) 2020-05-04
PH12020500376A1 (en) 2020-12-07
EP3449931A1 (en) 2019-03-06
EP3675879B1 (en) 2021-09-15
PL3675879T3 (pl) 2022-02-14

Similar Documents

Publication Publication Date Title
US9480658B2 (en) Modulation of synaptic maintenance
KR102676274B1 (ko) 세레브로리신의 용도
Ma et al. Propofol attenuates inflammatory damage via inhibiting NLRP1-Casp1-Casp6 signaling in ischemic brain injury
Broussalis et al. Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies
HK40026040B (en) Cerebrolysin for use in the treatment of cadasil
EA040978B1 (ru) Применение церебролизина
Chen et al. Exploring the protective effects of Qiju Granule in a rat model of dry age-related macular degeneration
Hayes Cellular Mechanisms of IGF-1 Neuroprotection After Ischemic Stroke
Noll Spatiotemporal Neuroprotection and Early Regeneration after Ischemic Stroke with Neuregulin-1 Treatment
Czapski et al. Genetic inactivation of poly (ADP-ribose) polymerase and endothelial nitric oxide synthase prevents energy failure and oxidative damage in the mouse brain during septic shock
Impairment et al. Diffusion Tensor Mr Imaging for Evaluation of Fronto-Subcortical Neural Pathway Changes in Parkinson's Disease With Dementia
Yenari Hsp70 Inhibits Activation of Nuclear Factor κB by Preventing Phosphorylation of Its Inhibitor Protein, IkB: P385
Uno The Broad Therapeutic Time Window of KCL-440 Bases on Delayed Activation of Poly (ADP-ribose) polymerase After Transient Ischemic Insults in Rats: P393
Herrup Hypoxic Preconditioning Reduces Select Cell Cycle–Related Processes After Reversible Middle Cerebral Artery Occlusion: P376
Zuccarello Local Brain Hypothermia Markedly Reduces Vasogenic Edema Development in a Porcine Intracerebral Hemorrhage Model: P390
Graf The Value of Translational Research in Acute Focal Ischemia: Comparison of Cat MCA Occlusion and Malignant MCA Infarction: P373
Neumann-Haefelin Tissue Plasminogen Activator–Mediated Blood-Brain Barrier Damage Is Dependent on Interactions Between the Thrombolytic Agent and Blood Clots in Transient Focal Cerebral Ischemia: P384
Minematsu Location of Hematoma in Acute Brain Hemorrhage During Antithrombotic Therapy: P367
Morishita Recovery of Cognitive Function With Gene Therapy Using Hepatocyte Growth Factor Gene After Ischemic Stroke: P389
Kim Activation of FOXO3a Transcription Factor Involves Neuronal Cell Death After Focal Cerebral Ischemia in Rats: P394
Chopp Low-Energy Laser Irradiation Applied Transcranially 24 Hours Following Induction of Stroke in the Rat Significantly Improves Long-Term Neurological Deficits: P399
Khatri Prospective Evaluation of Treatment of Acute Hypertension in Patients With Intracerebral Hemorrhage Using American Heart Association Guidelines: P368
Steinberg Hypothermia Attenuates the Decrease in Phosphorylation of Proteins in Akt Cell Signal Pathway After Permanent Middle Cerebral Artery Occlusion in Rats: P398
Wijman Utility of Magnetic Resonance Imaging in the Diagnosis and Management of Intracerebral Hemorrhage: P370
Yoon Inhibition of Postischemic Inflammation Reduced Early Endogenous Neurogenesis in Rat Stroke Model: P375

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200310

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210810

Comment text: Request for Examination of Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240410

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240613

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240614

End annual number: 3

Start annual number: 1

PG1601 Publication of registration